Together, these data suggest that the circulating SASP milieu underlies age-related endothelial dysfunction and its detrimental effects are in part mediated by CXCL12 and largely reversed by senolytic treatment with fisetin. This evidence concerns the gene CXCL12 and endothelial dysfunction.